157 terminated. 157 Phase 2, 32 Phase 1, 19 Phase 3.
By phase and status
Follow Congenital Abnormalities: new trials by email Literature Review of Congenital Abnormalities trials Research Report on Congenital Abnormalities
Trials (filtered) newest first · largest first
All 157 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS) No intervention, GTX-102 - Angelman Syndrome | Phase 2 | Terminated | 55 | 2025-10-13 | 2026-11-03 |
A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis BGB-45035, Placebo - Rheumatoid Arthritis | Phase 2 | Terminated | 49 | 2025-08-21 | 2026-05-28 |
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment Vosoritide Injection - Noonan Syndrome | Phase 2 | Terminated | 18 | 2024-11-22 | 2026-11-13 |
Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy OCA, Matching Placebo - Biliary Atresia | Phase 2 / Phase 3 | Terminated | 28 | 2024-09-02 | 2026-07-07 |
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency INZ-701 - Gene Mutations, Pseudoxanthoma Elasticum | Phase 2 | Terminated | 22 | 2024-06-19 | 2026-10-19 |
Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 AUR-201 - Microtia | Phase 1 / Phase 2 | Terminated | 1 | 2024-01-26 | 2025-11-21 |
Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia AUR-201 - Microtia | Phase 1 / Phase 2 | Terminated | 3 | 2024-01-26 | 2025-11-21 |
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) CRD-4730, Placebo - CPVT1, Heart Defects, Congenital | Phase 2 | Terminated | 7 | 2023-11-07 | 2026-05-27 |
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome DS-2325a, Placebo - Netherton Syndrome | Phase 1 / Phase 2 | Terminated | 9 | 2023-09-28 | 2026-05-14 |
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | 43 | 2023-06-12 | 2026-03-12 |
Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2). LQT-1213, Placebo, Dofetilide 250 μg Cap - Long QT Syndrome | Phase 1 / Phase 2 | Terminated | 42 | 2023-03-12 | 2025-07-24 |
A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN) SBT101 Treatment - AMN, AMN Gene Mutation | Phase 1 / Phase 2 | Terminated | 9 | 2022-11-17 | 2026-08-26 |
A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome RAD011, Placebo - Prader-Willi Syndrome | Phase 2 / Phase 3 | Terminated | 4 | 2022-04-13 | 2023-10-19 |
Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant Alpelisib, Fulvestrant, Metformin XR - Breast Cancer | Phase 2 | Terminated | 2 | 2022-04-06 | 2024-10-09 |
Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | 5 | 2021-12-15 | 2024-08-07 |
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH Tildacerfont - Congenital Adrenal Hyperplasia, 21-OHD | Phase 2 | Terminated | 67 | 2021-12-10 | 2025-12-24 |
Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | 7 | 2021-12-08 | 2024-07-12 |
Clinical Trial to Assess the Safety and Efficacy of Investigational Product in Patients Due to Hypospadias Treatment Failure "Ex vivo" expanded autologous human oral epithelium containing stem cells - Hypospadias | Phase 1 / Phase 2 | Terminated | 1 | 2021-11-26 | 2024-11-12 |
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa RNA antisense oligonucleotide for intravitreal injection - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 | Terminated | 21 | 2021-09-16 | 2024-08-07 |
The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis Danazol, Placebo - Pulmonary Fibrosis, Telomere Shortening | Phase 2 | Terminated | 29 | 2021-09-07 | 2025-08-05 |
Showing 20 of 157. Sign in to see all of them.
Narrower conditions
Leukemia, Myeloid, Acute (32) · Leukemia (19) · Blast Crisis (14) · Leukemia, Erythroblastic, Acute (14) · Leukemia, Megakaryoblastic, Acute (13) · Leukemia, Monocytic, Acute (13) · Hereditary Sensory and Autonomic Neuropathies (12) · Leukemia, Myelomonocytic, Acute (12) · Myelodysplastic Syndromes (12) · Heart Defects, Congenital (11) · Leukemia, Myeloid, Accelerated Phase (11) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Leukemia, Myelomonocytic, Chronic (8) · Myeloproliferative Disorders (8)
Broader conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (157) · Genetic Diseases, Inborn (70) · Neoplasms (57) · Neoplasms by Histologic Type (52) · Hemic and Lymphatic Diseases (50) · Pathological Conditions, Signs and Symptoms (50) · Hematologic Diseases (48) · Nervous System Diseases (43) · Cardiovascular Diseases (40) · Leukemia, Myeloid (35) · Bone Marrow Diseases (34) · Pathologic Processes (34) · Skin and Connective Tissue Diseases (31) · Abnormalities, Multiple (29)
Interventions
fludarabine phosphate (12) · Peripheral Blood Stem Cell Transplantation (11) · Whole-Body Irradiation (8) · Cyclophosphamide (7) · Tacrolimus (7) · Busulfan (6) · Cyclosporine (6) · Cytarabine (6) · Mycophenolic Acid (6) · Antilymphocyte Serum (5) · Methotrexate (5) · Sirolimus (5) · Cord Blood Stem Cell Transplantation (4) · Etoposide (4) · Filgrastim (4)
Sponsors
Fred Hutchinson Cancer Center (9) · Masonic Cancer Center, University of Minnesota (5) · Novartis Pharmaceuticals (5) · Laboratoires Thea (4) · M.D. Anderson Cancer Center (4) · Roswell Park Cancer Institute (4) · Boston Children's Hospital (3) · City of Hope Medical Center (3) · Holostem s.r.l. (3) · Incyte Corporation (3) · National Cancer Institute (NCI) (3) · Radius Pharmaceuticals, Inc. (3) · Spruce Biosciences (3) · The Hospital for Sick Children (3) · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (2)
Countries
United States (124) · France (28) · United Kingdom (22) · Canada (21) · Germany (21) · Italy (21) · Spain (21) · Australia (16) · Netherlands (13) · Belgium (10) · Israel (10) · Austria (7) · Poland (7) · Switzerland (7) · China (6)
Top investigators
Srdan Verstovsek (3) · Ahmed Elkashef, MD (2) · Daniel J. Weisdorf, MD (2) · Eric Jonasch, MD (2) · Johann W. Bauer, MD (2) · Lynda Szczech, MD (2) · Michele De Luca, MD/Professor (2) · Roland Walter (2) · Scott R. Solomon, MD (2)
Results publications
PMID 39356039, PMID 16899778, PMID 18926212, PMID 19910321, PMID 22105611, PMID 22133771, PMID 22294344, PMID 24037890, PMID 24705452, PMID 24906491, PMID 25223501, PMID 26053664, PMID 26855682, PMID 26908949, PMID 26912555, PMID 27143789, PMID 27599328, PMID 28118536, PMID 29175429, PMID 31215818, PMID 33159213, PMID 33639990, PMID 34783716, PMID 34857525, PMID 35007144, PMID 35283460, PMID 35545446, PMID 36204243, PMID 36394867, PMID 36408876, PMID 36535535, PMID 37280688, PMID 37875771, PMID 38290135, PMID 38710951, PMID 38829703, PMID 39607014, PMID 39625244, PMID 40713644, PMID 40762274, PMID 41217321, PMID 41385299
NIH funding
P30CA015704 (5), 2019 (4), 2018 (3), 2016 (2), 2017 (2), N01CM62202 (2), P01CA018029 (2), P30CA016056 (2), 2008 (1), N01CM62204 (1), P30CA016058 (1), P30CA022453 (1), P30CA043703 (1), P30CA124435 (1), R01AI053193 (1)